Kedokteran & Kesehatan editorial
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
The core problem
Innovation
The SNAP trial is an adaptive platform trial, a type of clinical trial design that allows for simultaneous evaluation of multiple interventions and adaptation of the trial based on accumulating data. Key design features include:
- **Platform structure**: The trial is organized around a master protocol with multiple domains, each addressing a different question about SAB management (e.g., antibiotic choice, duration, adjunctive therapies).
- **Adaptive randomization**: Participants are randomized to available treatment options within each domain, with randomization probabilities updated based on emerging evidence to favor more effective treatments.
- **Bayesian analysis**: The trial uses Bayesian statistical methods to incorporate prior knowledge and to allow for frequent interim analyses and adaptation.
- **Shared control group**: A common control group is used across domains to increase efficiency and reduce sample size.
- **Broad eligibility**: The trial aims to enroll a diverse population of patients with SAB infection across multiple countries.
The trial targets a sample size of 7000 participants, which is substantially larger than previous SAB trials, to provide adequate power to answer multiple questions. The adaptive design allows for dropping ineffective treatments early and adding new questions as needed.
Mathematically, the adaptive randomization can be represented as:
where represents the current evidence for treatment (e.g., posterior probability of benefit). This ensures that more participants are assigned to treatments that appear more promising.
A Mermaid diagram illustrating the platform structure is shown below:
Why it matters
Who should read this
Opening member content…